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Abstract 
Background: Prostate cancer is the most commonly diagnosed and prevalent malignancy reported to Australian 
cancer registries, with numerous studies from single institutions summarizing patient outcomes at individual hospitals 
or States. In order to provide an overview of patterns of care of men with prostate cancer across multiple institutions 
in Australia, a specialized dataset was developed. This dataset, containing amalgamated data from South Australian 
and Victorian prostate cancer registries, is called the South Australian-Victorian Prostate Cancer Health Outcomes 
Research Dataset (SA-VIC PCHORD).
Results: A total of 13,598 de-identified records of men with prostate cancer diagnosed and consented between 2008 
and 2013 in South Australia and Victoria were merged into the SA-VIC PCHORD. SA-VIC PCHORD contains detailed 
information about socio-demographic, diagnostic and treatment characteristics of patients with prostate cancer in 
South Australia and Victoria. Data from individual registries are available to researchers and can be accessed under 
individual data access policies in each State.
Conclusions: The SA-VIC PCHORD will be used for numerous studies summarizing trends in diagnostic character-
istics, survival and patterns of care in men with prostate cancer in Victoria and South Australia. It is expected that in 
the future the SA-VIC PCHORD will become a principal component of the recently developed bi-national Australian 
and New Zealand Prostate Cancer Outcomes Registry to collect and report patterns of care and standardised patient 
reported outcome measures of men nation-wide in Australia and New Zealand.
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Findings
Background
Clinical quality registries have been established in various 
healthcare settings to capture and provide measurement 
and longitudinal benchmarking of patients’ demographic, 
clinical and quality of life (QOL) data. The main function 
of these registries is to deliver this information and feed-
back to healthcare providers for quality management and 
to implement practice changes of clinical and economic 
significance [1–3]. Many registries serve as tools for clini-
cal trials in monitoring drug safety and efficacy and cost-
effectiveness for various conditions, including surgical, 
neurological, renal, rheumatology, gynaecology, heart, 
trauma and others [4–7]. Hundreds of research reports 
and publications arising from studying clinical registry 
data in the US, Europe, some Asian countries as well as 
in Australia can be found in the scientific literature [1, 2, 
8–14].
Cancer is one of the most frequent health condi-
tions where clinical quality registries are widely used to 
inform, monitor and evaluate trends in incidence, sur-
vival and management of health services and patient 
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outcomes [15–19]. Prostate cancer is the most com-
monly diagnosed and prevalent malignancy reported to 
Australian cancer registries and globally, with numerous 
studies using registry data and sampling to report on 
patterns of care, treatment options and long-term sur-
vival [20–26].
While long term survival following a diagnosis of pros-
tate cancer is relatively good (~92 % at 5 years) [27], there 
is considerable morbidity associated with the treatment 
and management of prostate cancer. Currently little 
research has examined the effectiveness of various treat-
ment pathways within the Australian setting. Much of 
the evidence that guides clinical management decisions 
in Australia has been derived from international studies. 
It is unclear whether clinical characteristics, treatment 
patterns and outcomes among Australian men are com-
parable with those of men in the USA or Europe, where 
much of the international research is based [21, 28].
To address these questions numerous studies have been 
conducted using data from prostate cancer registries in 
South Australia and Victoria in Australia. However, these 
studies have been limited to hospital groups within sin-
gle states and have not examined patterns across multi-
ple jurisdictions [20, 21, 28, 29]. Studies across multiple 
jurisdictions and multiple registries would generally pro-
vide broader coverage and strengthen the evidence base 
for evaluating patterns of care and patient outcomes; and 
point to opportunities for improving health outcomes 
of men with prostate cancer in Australia. Results from 
multiple institutions would generally be more powerful 
than those from single jurisdictions as they would be well 
placed to find and control for additional sources of vari-
ation and take advantage of natural policy experiments 
[30–32].
Victoria and South Australia represent 32 % of the Aus-
tralian population. Both states have distinct demographic 
profiles, which collectively reflect the population distri-
bution across Australia. Most of South Australia’s popu-
lation (85  %) resides in the inner or outer urban areas 
of the capital city, with a small proportion residing in 
remote locations that are quite distant from health care 
services, similar to the states of Western Australia and 
the Northern Territory [33]. In these states, tertiary care 
is centralised in the capital cities; hence radical treatment 
for prostate cancer is generally only available in metro-
politan hospitals. In contrast, a larger proportion of the 
population of Vic reside in major centres outside the 
capital city, and tertiary care tends to be more decentral-
ised, similar to other eastern states. While geographical 
access to health care services differs across states, par-
ticularly access to tertiary hospitals, universal health care 
(including free hospital care) is available to all Australian 
residents.
The main objective of this study was to develop a South 
Australian-Victorian Prostate Cancer Health Outcomes 
Research Dataset (SA-VIC PCHORD) in order to pro-
vide an overview of socio-demographic and clinical char-
acteristics as well as treatment patterns and outcomes 
of prostate cancer patients across two Australian states. 
This paper will present a technical description of SA-VIC 
PCHORD, containing merged records from two clinical 
registries in the states of SA and Vic, Australia. These 
states were selected for this study as they are currently 
the only two established longitudinal, third-party col-
lected prostate cancer registries in this country.
Methods
Prostate Cancer Health Outcomes Research Unit (PCHORU)
In 2013, the Movember Foundation, a Men’s Health 
Charity Organisation, funded an initiative to seek con-
sensus on implementation of the Australian and New 
Zealand Prostate Cancer Outcomes Registry (PCOR–
ANZ) [14]. Subsequently, research collaboration has 
been established between the University of South Aus-
tralia, Monash University, the Movember group and the 
South Australian Health and Medical Research Institute 
(SAHMRI) to establish the Movember Prostate Cancer 
Health Outcomes Research Unit (PCHORU). Unit aims 
include: (1) investigating risk adjusted treatment out-
comes and care patterns for Australian men with prostate 
cancer, (2) assessing quality and appropriateness of care, 
(3) comparing care patterns and outcomes of prostate 
cancer with international benchmarks, (4) investigat-
ing socio-demographic inequalities in cancer treatment, 
(5) investigating survivorship and quality of life of men 
with prostate cancer, (6) developing improved methods 
of risk stratification for prostate cancer, (7) developing 
an improved composite outcome indicator of effective-
ness of prostate cancer care, (8) and undertaking other 
research directed at improving outcomes of prostate can-
cer for men and their partners. To address these aims, the 
Unit will conduct a series of studies, using retrospective 
data from the South Australian and Victorian prostate 
cancer registries. Most importantly, based on results, 
action plans will be developed to increase the quality and 
effectiveness of prostate cancer care in Australia.
Data sources
To address PCHORU goals, we developed a dataset, con-
taining amalgamated records of men with prostate can-
cer from South Australia and Victorian prostate cancer 
registries.
All men, above 18  years of age, who have been diag-
nosed or treated for prostate cancer in participating sites 
in SA or Vic, are eligible to participate in the registries. 
The method of identifying eligible patients is dependent 
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on the source of prostate cancer notifications. Notifica-
tions may come from individual hospitals, surgical cen-
tres, or pathology providers. Patient information and 
consent forms, explaining the registry, data collection, 
and option to opt-out at any time, are provided to all pro-
spective participants. A waiver of consent enables collec-
tion of diagnostic and treatment data on men who have 
died before providing consent, and on men diagnosed 
via a transurethral resection of the prostate (TURP), for 
whom consent must be obtained from their treating doc-
tor [14].
The Victorian Prostate Cancer Registry (now termed 
the Prostate Cancer Outcomes Registry-Victoria, or 
PCOR-Vic), based at Monash University, was established 
in 2008 [34]. The registry collects data on prostate cancer 
cases from 38 metropolitan and regional public and pri-
vate hospitals in Vic. Based on the latest update from Vic-
torian Cancer Registry [35], these sites account for about 
70 % of incidence prostate cancer cases in that State, and 
more than 10,000 men have been accrued. More infor-
mation detailing patients’ recruitment and methods for 
data collection, can be found elsewhere [28].
The South Australian Prostate Cancer Clinical Out-
comes Collaborative (SA-PCCOC) database, based in 
South Australia, was established in 1998 to include men 
with prostate cancer at three major teaching and treat-
ment hospitals in South Australia [36]. The database has 
been expanded more recently to include private treat-
ment facilities. Currently the registry contains data on 
more than 10,000 patients. Approximately 75  % of the 
urologists practicing in South Australia are actively 
engaged in recruiting participants and contributing data 
to SA-PCCOC. Coverage includes patients treated at 
all public hospitals and most private practices, includ-
ing public and private radiotherapy services. Details of 
the registry, including methods for data collection, are 
described elsewhere [20].
Both registries contain data on patient demographic 
characteristics, initial diagnosis and disease staging infor-
mation, prostate specific antigen (PSA) history, clinical 
examination results, treatment details, comorbidities and 
complications. Follow-up data are derived from the mon-
itoring of PSA values, clinical evidence of recurrence, any 
further biopsy and pathology reported, date and cause of 
death as well as patient reported symptoms and patient 
reported QOL data.
Ethics and permissions
Numerous meetings were held amongst PCHORU 
steering committee members, registry managers and 
researchers to determine what data items should be 
included in the SA-VIC PCHORD. A protocol describing 
inclusion, exclusion criteria, time frames and data items 
was then developed and human research ethics approv-
als for the project were obtained from Monash University 
and the University of South Australia. Data request appli-
cations detailing data items to be extracted were submit-
ted to each of the registries and the necessary data were 
extracted, de-identified and cleaned. Data extracted from 
the SA-PCCOC registry were sent to Monash University 
researchers, where it was merged with the PCOR-Vic 
data.
Data storage
The amalgamated dataset (SA-VIC PCHORD) is pass-
word protected and housed on a secure network at 
Monash University Department of Epidemiology and 
Preventive Medicine, Melbourne, Victoria. Monash Reg-
istry Database security is maintained using encryption of 
data, a managed and audited protocol for access, train-
ing and accreditation of personnel, role-based access and 
authentication of data. Monash Registry Databases are 
housed and managed in an ISO 27001 certified environ-
ment. The ISO 27001 certification incorporates the Pri-
vacy Act (1988) and Health Records Act (2001) within its 
applicability statement. [28].
A copy of the amalgamated dataset was sent to the SA-
PCOCC data custodian and is also stored on a secure 
password protected computer at The University of South 
Australia (School of Population Health, SAHMRI, Ade-
laide, South Australia). Access to the dataset is limited to 
the investigators of this study.
Data items included in SA‑VIC PCHORD
Patient characteristics
A total of 13,598 records of prostate cancer men diag-
nosed and consented between 2008 and 2013 in South 
Australia and Victoria were merged into the SA-VIC 
PCHORD. Data categories, individual variables, value 
labels and completeness of the SA-VIC PCHORD data 
are presented in Table 1.
Both the PCOR-Vic and SA-PCCOC registries col-
lect identifiable patient, clinician and treating institu-
tion information. To avoid identical entries, we checked 
patients’ name, surname, date of birth, date of diagno-
sis and clinician information. No identical entries were 
found in both registries. To protect privacy, and before 
merging data from the two registries, all identifiable 
data, such as names, patients’ dates of birth, residential 
addresses, clinicians’ surnames and hospital names were 
removed, and randomly created numbers (Patient Ids) 
were assigned to each case of the merged set. South Aus-
tralia and Victoria are neighbouring states; therefore it 
is possible that some patients seek care in the alternate 
state. A State variable, based on the origin of the diag-
nosing institution, has been created to identify patients 
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in both states, and it is assigned to each patient after his 
details have been entered to the registry; thus ensuring 
that no duplicated records occur.
After calculating age at the diagnosis, patient’s date of 
birth was deleted from the merged file. The age group 
variable was also created according Australian Bureau of 
Statistics (ABS) [37] 5 year age categories. A linkage with 
socio-economic indexes for areas (SEIFA) [38] on the 
basis of the patient residential postcode was performed 
and two additional data items (SEIFA decile and score) 
were created. SEIFA is a multidimensional area level 
measure of socioeconomic advantage and disadvantage 
based on characteristics of one neighbourhood relative to 
others. SEIFA was developed and validated (and regularly 
updated) by ABS using census data for collector districts 
and it is commonly used in Australian research studies. 
The SEIFA index is a composite of a number of average 
measures within an area including equivalent household 
income, occupancy type, level of educational attainment, 
level of employment/unemployment, occupational skill 
level, crowding, car ownership, marital status, housing 
and income support.
Date of death was available in both registries and was 
included into the merged dataset. In South Australia, 
vital status and cause of death (prostate cancer or other) 
is assessed through linkage with the state death registry, 
managed by the Office of Births Deaths and Marriages, 
and is updated regularly for individual cases where death 
is reported in the case notes or National Death Index. In 
Victoria, death information is received via data linkage 
with the Victorian Cancer Registry (which in turn peri-
odically links to the Victorian Registry of Births, Deaths 
and Marriages). In both cases, vital status was updated 
immediately prior to merging the data extracts from each 
state. Vital status, as well as the other data in the regis-
try, is regularly updated in each State, and the updated 
information is fed onto the SA-VIC PCHORD dataset on 
annual basis.
Diagnostic characteristics
Diagnostic information included date of diagnosis, type 
of diagnostic procedures, PSA levels, Gleason scores and 
clinical staging data. Type of diagnostic procedure was 
available for 96.9  % of patients and originally grouped 
into the following categories: Trans-rectal ultrasound 
(TRUS), transurethral resection of prostate (TURP), 
transperineal biopsy, clinical investigation methods such 
as computer tomography (CT), magnetic resonance 
(MRI), histology or others. Since the vast majority of 
patients were diagnosed by TURP or TRUS, these cat-
egories were re-coded into a new variable, consisting of 
three groups: (1) TRUS, (2) TURP, and (3) Other meth-
ods (“other” accounting for 3.1 % of patients).
PSA level at diagnosis was available for 86.6 % patients. 
For research purposes this variable was grouped into 
the four categories: (1) <4  ng/mL, (2) 4–10  ng/mL, (3) 
10–20  ng/mL and (4) >20  ng/mL. Missing PSA levels 
were classified as “unknown”. Primary, secondary, ter-
tiary and total Gleason scores were also included in the 
dataset and grouped into the following grade groups: 
(1) total Gleason score ≤6, (2) Gleason score 3 + 4, (3) 
Gleason score 4 + 3, (4) Gleason score 8, and (5) Glea-
son score  ≥9. Total Gleason score was available for 
97.5 % of cases. Missing Gleason scores were classified as 
“unknown”. The boundaries (cut-points) of Gleason score 
categories were chosen based on a recently published 
contemporary prostate cancer grading system [39].
Clinical T-category, N-category and M-category at 
diagnosis is based on the size and/or extent (reach) of 
the primary tumour (T), the amount of spread to nearby 
lymph nodes (N), and the presence of distant metastasis 
(M) or secondary tumours formed by the spread of can-
cer cells to other parts of the body [40]. Clinical T- cat-
egory was recorded for 53.4 %, N- and M- categories—for 
63.7 % cases. The National Comprehensive Cancer Net-
work (NCCN) risk criteria for disease progression were 
used to classify patients into low-, intermediate-, high- 
and very high/metastatic risk disease [41]. Where the 
clinical T category was not recorded, the patient was cat-
egorized as at low risk of disease progression if the Glea-
son score was ≤6 and the PSA concentration was <10 ng/
mL [21]. For those patients, whose PSA concentration 
and/or Gleason score was not available, but their clinical 
staging category was “T3b-T4” or “Any T, N1 or Any T, 
Any N, M1”, the risk of the disease was assigned to very 
high/metastatic. NCCN classification was calculated for 
92.4  % cases. Information on any subsequent biopsies 
was also available in both datasets and it was merged into 
SA-VIC PCHORD (Table 1).
Treatment characteristics
The first treatment type, which patients received and 
the date of treatment was recorded for 93 % of patients. 
Treatment types were coded differently in South Austral-
ian and Victorian source registries. However six major 
treatment categories could be used: (1) surgery (pros-
tatectomy), (2) radiotherapy, (3) androgen deprivation 
therapy (ADT), (4) active surveillance (AS), (5) watchful 
waiting (WW) and (6) others (i.e. high intensity focused 
ultrasound, chemotherapy etc.). For those patients whose 
treatment information was not recorded, treatment type 
was coded as “unknown”. Time to the treatment was cal-
culated as difference (in days) between dates of diagno-
sis and first treatment. Distance to treatment centre (in 
kilometres) was computed using geocoded residential 
and hospital information. [42]. All treating hospitals in 
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South Australia and 71 % of the hospitals in Victoria were 
metropolitan.
Information on any subsequent treatment was also 
available and was included in the SA-VIC PCHORD. 
Radiotherapy information included the type of the treat-
ment (i.e. radical, palliative or brachytherapy), start date, 
dose, fractions and dose rate (low or high). Surgery infor-
mation included operation date, type, surgical pathology 
Gleason scores, positive surgical margins and pathologi-
cal TNM categories. Hormone and chemotherapy treat-
ment details were also available for those who undertook 
these treatments and data included type and commence-
ment date. AS and WW were distinguished from each 
other as separate options as recorded in each registry.
Post‑diagnostic PSA measures
Both states’ registries record post-diagnostic PSA levels. 
In Victoria, PSA at the time of each new treatment was 
recorded to 24  months post-diagnosis, while in South 
Australia, all PSA measures were captured irrespec-
tive of time point. For the SA-VIC PCHORD, data were 
combined to include PSA level at or immediately prior 
to treatment. For South Australia, PSA measured at the 
closest date before each treatment was assigned as the 
‘treatment PSA’. Only PSA measures for treatment within 
2 years of diagnosis were included to be consistent with 
Victorian data. PSA levels at 12 and 24  months post 
diagnosis follow-up were also recorded in the combined 
data set. For South Australia, PSA levels recorded within 
1  month of the 12 and 24  month post-diagnosis were 
used for those follow-up points.
Discussion
This project merged data from two prostate cancer reg-
istries to develop an amalgamated research dataset to 
describe characteristics of men with prostate cancer in 
South Australia and Victoria. Amalgamated datasets con-
taining clinical information obtained from various data 
sources have been widely used for research purposes. 
A similar dataset was described by Choi et al. [43], who 
developed a prostate cancer research database system in 
Korea, incorporating information about a prostate can-
cer for research, including demographics, medical his-
tory, operation information, laboratory and QOL surveys 
from the CaPSURE database [44], the Japanese pros-
tate cancer registry and the Center for Prostate Disease 
Research database in the USA. Another research dataset 
was described by Pathy et al. [12], who merged two hos-
pital-based breast cancer databases (University Malaya 
Medical Center, Malaysia, and National University Hos-
pital, Singapore) into a regional registry of breast cancer 
patients diagnosed between 1990 and 2007. Methods to 
create clinical datasets containing linked and merged 
data were also summarized by Pates et al. [11] who pre-
sented their methodology and the impact of merging 
detailed state-wide mortality data into the master patient 
index tables of the clinical data repository (CDR) of the 
University of Virginia Health System (USA) to assist 
caregivers in identification of at-risk patient groups by 
description of those patients in the CDR who have com-
mitted suicide.
Strengths and limitations
The main strength of the SA-VIC PCHORD is the use of 
clinical registry data, containing a detailed diagnosis and 
treatment information of the patients with prostate can-
cer. PCOR-Vic and SA-PCCOC enable rapid and reliable 
ascertainment of patterns of care relating to men diag-
nosed with prostate cancer and provide reports back to 
treating clinicians in regional and metropolitan Victo-
ria and South Australia [28, 36]. Demographic, diagno-
sis and treatment data are periodically updated in both 
registries, and will be annually included into the SA-VIC 
PCHORD dataset.
However, some limitations to this study also need to be 
noted. Firstly, there was a variation in type and nature of 
certain data items in both registries as a result of which 
they could not be merged. For example, the type of hos-
pital where a patient was treated in Victoria was coded 
as “private” or “public” depending on the hospital type; 
however this information was not available in South Aus-
tralia. In the SA-PCCOC database, patients are classified 
as being either ‘public’ or ‘private’ rather than classifying 
health care facilities.
Another issue relates to missing data: for example, PSA 
level at diagnosis was missing for 13.4 % of cases and clin-
ical T- stage was not available for nearly half of patients, 
which was crucial when calculating NCCN staging [45]. 
A similar problem occurred with treatment information. 
Treatment type was not recorded for 7 % of cases, which 
made it difficult to interpret whether these patients did 
not have any treatment, or were under active surveillance 
or WW.
Quality of life data from the two datasets could not be 
merged due to systematic differences in administration 
methods, tools used and data collection time points. At 
12 and 24  months after the date of diagnosis, partici-
pants in Victoria were contacted by telephone to verify 
management details and to measure general health and 
disease specific patient reported outcomes about their 
urinary, bowel and sexual function [28]. In South Aus-
tralia, a disease specific tool EPIC-26 [46] is administered 
as a written postal survey. It is sent out to men after they 
are aware of their diagnosis, but before treatment com-
mences (usually within 3  months of diagnosis), then 
again at 3, 6, 12, 24, 36 and 60 months post treatment.
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Future directions
It is anticipated that the dataset described in this 
paper will be used for numerous studies summariz-
ing trends, survival and patterns of care in men with 
prostate cancer in Victoria and South Australia. The 
recently developed PCOR-ANZ registry will collect 
patterns of care and standardised patient reported 
QOL measures of men nation-wide in Australia and 
New Zealand [14]. EPIC-26 survey [46] will be admin-
istered to all the participants, including those, whose 
data have been already merged into SA-VIC PCHORD, 
prior to treatment, and at 12 months post final active 
treatment. This information will be incorporated 
into the SA-VIC PCHORD. It is envisaged that in the 
future, data for men with prostate cancer collected by 
the PCOR-ANZ registry will be incorporated into the 
SA-VIC PCHORD, leading to the PCHORD expanding 
nationwide. We expect that various data analyses will 
be conducted in order to assist transforming health-
care for men with prostate cancer in Australia and 
New Zealand in a standardised way.
Availability and requirements
  • Project name: South Australian-Victorian Prostate 
Cancer Health Outcomes Research Dataset.
  • Project home page: http://pcr.registry.org.au/; http://
www.sa-pccoc.com.
  • Operating system(s): platform independent.
  • Programming language: SQL.
  • Other requirements: not applicable.
  • License: not applicable.
  • Any restrictions to use by non-academics: not appli-
cable.
Availability of supporting data
Data from individual registries is available under indi-
vidual data access policy in each state. Access to the data 
is guided by strict protocols and procedures to ensure 
that the privacy of men and other ethical principles are 
maintained at all times. The data access policy and data 
request form for the PCOR-Vic is available to access by 
registering through the website address at http://www.
pcr.registry.org.au/Home.aspx. Information about the 
SA-PCCOC data can be found at http://www.sa-pccoc.
com. Requests to access data from the SA-PCCOC reg-
istry should be addressed to the research committee for 
review and consideration (contactus@sa-pccoc.com). 
The following should be addressed in each data request: 
analysis strategy, data availability, publication plan-
ning, ethics requirements, funding options and student 
supervision. The research committee review process 
receives input from diverse disciplines including urology, 
radiation oncology, medical oncology, epidemiology and 
data management. A data agreement will be required for 
each study and researchers are encouraged to provide 
financial support to facilitate their request. Requests for 
data to support commercial activities are not considered.
SA-VIC PCHORD is currently used for research pur-
poses by the researchers listed under the institutional 
ethics protocols in South Australia and Victoria. Requests 
for SA-VIC PCHORD data can be accepted from external 
researchers and will be considered on individual basis. It 
is anticipated, that once PCOR-ANZ data is collected and 
included into national prostate cancer health outcomes 
research dataset, researchers will be able to access this 
data following the processes described elsewhere [14].
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